

DIAGNOSTIC CONFIDENCE: IT'S IN THE DNA

Enhance your clinical decision making with the SPECTRALIS® imaging platform for retina and glaucoma. The true potential of multimodal diagnostic imaging awaits you.

No matter how you configure your SPECTRALIS, you can be sure it contains the core DNA for high contrast, high resolution images that cut through the noise and give you the confidence to pinpoint pathology, identify real change and make more informed clinical decisions.

SPECTRALIS offers an upgradeable, multimodal platform with confocal fundus imaging, TruTrack Active Eye Tracking, retinal recognition, noise reduction and 10 layer visualization. These features form the core of the SPECTRALIS DNA for diagnostic confidence. As new technology becomes available, it is simple to add new imaging modalities to the SPECTRALIS, providing additional information to enhance clinical decision-making, while preserving patient data for follow-up.

SPECTRALIS modular options include:

- Glaucoma Module Premium Edition
- MultiColor Module
- BluePeak Module
- Anterior Segment Module
- OCT2 Module
- OCT Angiography Module*
- Scanning Laser Angiography
- Widefield Imaging Module
- Ultra-Widefield Imaging Module




Confocal scanning laser ophthalmoscopy (cSLO) provides high contrast, high quality images, even in challenging patients with media opacities. Live fundus assessment with simultaneously-captured OCT enables you to identify and capture pathology in real time, providing complementary diagnostic information. The SPECTRALIS averages up to 100 B-scans in the same location to remove noise and provide high resolution OCT images for visualization of 10 retinal layers, to help you pinpoint and assess pathology.

TruTrack Active Eye Tracking is patented technology that uses a second laser beam to actively track the eye during OCT scanning to avoid motion artifacts. It effectively "freezes" the retina, allowing you to capture the precise OCT image you want, even if the patient blinks or moves. The retinal recognition technology automatically repositions the OCT scan in the same anatomic location at follow-up for incredible accuracy. Detect changes as small as 1 micron and confidently monitor disease progression over time.

To learn more about the DNA of SPECTRALIS visit www.spectralis-oct.com.

**The SPECTRALIS OCT Angiography Module has not been cleared by the FDA for use in the United States.*

**HEIDELBERG
ENGINEERING**



Multimodal imaging

www.spectralis-oct.com